Glenmark Pharmaceuticals recalled 14,976 bottles of Carvedilol Tablets on August 6, 2025. The recall follows findings of N-Nitroso Carvedilol Impurity-1 above FDA limits. Consumers should stop using the product immediately and contact their healthcare provider.
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Carvedilol Tablets, USP, 25 mg, packaged in 500 tablets per carton. The affected lot numbers are 17241213, 17241215, and 17241224, with an expiration date of June 2026.
The recall stems from CGMP deviations, specifically elevated levels of N-Nitroso Carvedilol Impurity-1 (NNCI) exceeding the FDA-recommended limit of 4.0 ppm. This impurity poses potential health risks.
No injuries or incidents have been reported related to this recall. The hazard level is classified as high due to the potential risks associated with the impurity.
Consumers and healthcare providers should stop using Carvedilol Tablets immediately. Contact Glenmark Pharmaceuticals Inc., USA, or your healthcare provider for further guidance.
For more information, consumers can visit the FDA's recall page or contact Glenmark Pharmaceuticals Inc. at their USA office.
Get instant alerts for recalls that affect you. Free forever.
Glenmark Pharmaceuticals recalled nearly 97,000 packs of Ondansetron Orally Disintegrating Tablets on December 30, 2025. Defective blister packs may not fully seal, leading to tablets falling out. Consumers should stop using the product immediately and contact healthcare providers.
Novo Nordisk recalled Wegovy (semaglutide) injections on December 19, 2025, after discovering hair in prefilled syringes. The contamination poses a serious hazard to consumers. The recall affects all units distributed nationwide.
Novo Nordisk recalled Wegovy (semaglutide) Injection on December 19, 2025, due to hair found in a prefilled syringe. The recall affects products distributed nationwide in the United States. Consumers should stop using the product immediately and contact their healthcare provider.
Zydus Pharmaceuticals recalled over 2,100 bottles of TraZODONE Hydrochloride Tablets on December 19, 2025. Some tablets have surface dents that may affect medication integrity. Consumers should stop using the product immediately and seek guidance from healthcare providers.
CareFusion 213, LLC recalled 106,400 units of ChloraPrep Triple Swabsticks on December 17, 2025. The recall occurred due to a lack of assurance of sterility. Consumers must stop using the product immediately and contact CareFusion for guidance.
Merck Sharp & Dohme LLC recalled 845 kits of Noxafil Powdermix on December 12, 2025. The recall follows the discovery of potential metal particulates in the product. Consumers should stop using the medication immediately and contact their healthcare provider for further guidance.
Merck Sharp & Dohme LLC recalled 3 single-dose kits of Emend (aprepitant) on December 12, 2025. The recall stems from the potential presence of metal particulates in the medication. Consumers should immediately stop using the product and contact their healthcare provider for guidance.
Beaver-Visitec International recalled five units of the OME6000U Laser and Endoscopy System on December 5, 2025. The recall stems from a manufacturing deviation where ferrites required for the USB cable were not installed. This omission poses a high electrical hazard risk to patients and healthcare providers.